Climbing Mt. Everest presents another risk with the latest medical revelation that its high altitude level will likely cause Type 2 Diabetes.
Oxygen level at its peak may cause the human body to react from low oxygen intake known as hypoxia. Many studies have linked this condition to insulin resistance in the body.
The Caudwell Xtreme Everest, in coordination with the Centre for Altitude Space and Extreme Environment Medicine (CASE Medicine), conducted a study involving experiments on 24 participants who climbed high altitudes. Half of the group climbed the peak at 8,848 meters while the rest took the 5,300-meter height. All of participants were assessed for glucose control, weight changes and inflammation biomarkers, and were re-evaluated on the sixth and eighth weeks.
The study, published in the journal PLOS ONE, revealed that the group who reached the peak registered significant increase in insulin resistance on its biomarkers after 6-8 weeks. The study proponents attribute this to the group’s exposure to hypoxia or low oxygen levels.
Professor Mike Grocott who led this research shared via a news release that “these results have given us useful insight into the clinical problem of insulin resistance”. He further stressed that this study provides comparative analysis on their findings of hypoxia on obese individuals and healthy people who are exposed to high altitudes. These results could play a significant role in finding appropriate medical intervention for diabetic patients.